With the hold lifted, Amylyx can begin screening and enrolling for its Phase 1 LUMINA trial, which will test AMX0114 in ALS ...

The Massachusetts based biotech will now press ahead with human trials for its antisense oligonucleotide (ASO) therapy, ...

Amylyx Pharmaceuticals Inc (AMLX) stock saw a decline, ending the day at $3.45 which represents a decrease of $-0.15 or -4.17% from the prior close of $3.6. The stock opened at $3.43 and touched a low ...

The FDA is putting Atara’s active Investigational New Drug applications on hold due to manufacturing concerns at a ...

The biotech said it has dosed the first participant in a Phase 3 study of its in vivo gene editing treatment. Elsewhere, the FDA imposed a hold on Atara and lifted another on Amylyx.

Canary Cure Therapeutics (Canary Global Inc.) has released preclinical results for its lead candidate, CCT-217, an siRNA therapeutic targeting cannabinoid CB1 receptor (CB1R) and zinc finger protein ...

This is the latest venture for Amylyx into the ALS field after its previous therapy Relyvrio was pulled from the market in ...

Shares of Amylyx Pharmaceuticals (NASDAQ:AMLX) fell 13% in morning trading Tuesday amid news that an FDA clinical hold on a Phase 1 study for its ALS drug candidate AMX0114 has been lifted. Amylyx ...

CAMBRIDGE, Mass. - Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX), a $245.1 million market cap biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical ...

The company in March said its ALS drug Relyvrio had failed a late-stage clinical trial, and the stock has sunk more than 78% over the past year. Amylyx pulled Relyvrio from the market, cut its ...

After raising questions surrounding dosing levels, the FDA has freed Amylyx’s early-stage amyotrophic lateral sclerosis (ALS) ...

March of Dimes, the organization fighting for the health of all moms and babies, has named Dr. Kimberly O'Brien, Professor of ...